Yanbing Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yanbing Gong has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Churan Wang
Dongzhimen Hospital, Beijing University of Chinese Medicine
8 shared publicationsAijing Li
Dongzhimen Hospital, Beijing University of Chinese Medicine
7 shared publicationsJingyi Guo
Dongzhimen Hospital, Beijing University of Chinese Medicine
7 shared publicationsYijia Jiang
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
7 shared publicationsDan Yin
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
6 shared publicationsMaoying Wei
Dongzhimen Hospital, Beijing University of Chinese Medicine
6 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1901899
The association between the triglyceride-glucose index and diabetic peripheral neuropathy: a systematic review and meta-analysis
Background: Diabetic peripheral neuropathy (DPN) is a prevalent and severe microvascular complication of type 2 diabetes mellitus (T2DM). Early risk screening and warning are critical for slowing disease progression. The triglyceride-glucose (TyG) index, a simple and efficient surrogate marker for assessing insulin resistance (IR), has been proven to be closely associated with various diabetic complications. However, existing studies on the association between the TyG index and the risk of DPN have yielded inconsistent findings, and relevant evidence still lacks systematic synthesis. Methods: A systematic review and meta-analysis were conducted. We systematically searched databases including PubMed, Embase, Web of Science, CNKI, Wanfang, and CQVIP to enroll observational studies exploring the association between the TyG index and the risk of DPN in patients with T2DM. Two investigators independently performed literature screening, data extraction, and quality assessment. The random-effects and fixed-effects models were applied to pool effect sizes, and subgroup analyses were carried out to explore potential sources of heterogeneity. Results: A total of 14 studies involving 32,281 participants were included. The results showed that a higher TyG index was associated with an increased risk of DPN, with a pooled odds ratio (OR) of 2.614 (95% CI: 1.788-3.821, P < 0.0001) and a pooled hazard ratio (HR) of 1.248 (95% CI: 1.003-1.553, P = 0.0471). This positive correlation remained consistent across most subgroups stratified by age, sample size, BMI, and adjustment for confounding factors. However, the association did not reach statistical significance in the non-China subgroup. Conclusion: Elevated TyG levels are associated with an increased risk of DPN in patients with T2DM. However, the causal relationship requires further validation. These findings may serve as a reference for clinical screening of DPN risk. Systematic Review Registration: https://www.crd.york.ac.uk/prospero , identifier CRD420261373476.
- 4 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1901899
Open AccessThe association between the triglyceride-glucose index and diabetic peripheral neuropathy: a systematic review and meta-analysis
Background: Diabetic peripheral neuropathy (DPN) is a prevalent and severe microvascular complication of type 2 diabetes mellitus (T2DM). Early risk screening and warning are critical for slowing disease progression. The triglyceride-glucose (TyG) index, a simple and efficient surrogate marker for assessing insulin resistance (IR), has been proven to be closely associated with various diabetic complications. However, existing studies on the association between the TyG index and the risk of DPN have yielded inconsistent findings, and relevant evidence still lacks systematic synthesis. Methods: A systematic review and meta-analysis were conducted. We systematically searched databases including PubMed, Embase, Web of Science, CNKI, Wanfang, and CQVIP to enroll observational studies exploring the association between the TyG index and the risk of DPN in patients with T2DM. Two investigators independently performed literature screening, data extraction, and quality assessment. The random-effects and fixed-effects models were applied to pool effect sizes, and subgroup analyses were carried out to explore potential sources of heterogeneity. Results: A total of 14 studies involving 32,281 participants were included. The results showed that a higher TyG index was associated with an increased risk of DPN, with a pooled odds ratio (OR) of 2.614 (95% CI: 1.788-3.821, P < 0.0001) and a pooled hazard ratio (HR) of 1.248 (95% CI: 1.003-1.553, P = 0.0471). This positive correlation remained consistent across most subgroups stratified by age, sample size, BMI, and adjustment for confounding factors. However, the association did not reach statistical significance in the non-China subgroup. Conclusion: Elevated TyG levels are associated with an increased risk of DPN in patients with T2DM. However, the causal relationship requires further validation. These findings may serve as a reference for clinical screening of DPN risk. Systematic Review Registration: https://www.crd.york.ac.uk/prospero , identifier CRD420261373476.
- Open Access
- 24 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14  (7) , 1427
Research Progress on Downstream Mechanisms of Glucose Metabolic Reprogramming and Its Role in the Occurrence and Progression of Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is a highly prevalent and devastating chronic metabolic disease worldwide, with pathogenesis centrally characterized by insulin resistance and pancreatic β-cell dysfunction. Accumulating evidence has demonstrated that glucose metabolic reprogramming represents an adaptive metabolic shift from oxidative phosphorylation to aerobic glycolysis in cells in response to a hyperglycemic microenvironment. This shift acts as an upstream important event driving the initiation and progression of T2DM. This review summarizes the characteristics of glucose metabolic reprogramming in insulin-sensitive target organs under T2DM conditions, including the liver, skeletal muscle, adipose tissue and pancreatic β-cells. It also discusses four major downstream effector mechanisms: mitochondrial energy metabolism disturbance, augmented oxidative stress, disruption of mitochondria-associated endoplasmic reticulum membranes (MAMs) coupled with calcium homeostasis imbalance, and systemic inflammatory response. On this basis, we summarize the intervention strategies targeting the above signaling pathways, including antioxidant therapy, restoration of MAMs integrity and calcium homeostasis, systemic anti-inflammatory intervention, and multi-target regulatory effects of traditional Chinese medicine. Current studies indicate that early intervention in downstream stress events is induced by glucose metabolic reprogramming. This is particularly true for the preservation of MAMs’ integrity; restoration of calcium homeostasis; and inhibition of NLRP3 inflammasome activation, the latter of which is expected to block or delay the progression from prediabetes to clinical T2DM. Nevertheless, substantial gaps still remain in the understanding of the dynamic regulatory mechanisms of MAMs, tissue-specific therapeutic targets, and relevant clinical translational research. Future integration of multi-omics technologies will provide novel therapeutic strategies and theoretical foundations for the early prevention and treatment of T2DM.
- 24 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14  (7) , 1427
Open AccessResearch Progress on Downstream Mechanisms of Glucose Metabolic Reprogramming and Its Role in the Occurrence and Progression of Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is a highly prevalent and devastating chronic metabolic disease worldwide, with pathogenesis centrally characterized by insulin resistance and pancreatic β-cell dysfunction. Accumulating evidence has demonstrated that glucose metabolic reprogramming represents an adaptive metabolic shift from oxidative phosphorylation to aerobic glycolysis in cells in response to a hyperglycemic microenvironment. This shift acts as an upstream important event driving the initiation and progression of T2DM. This review summarizes the characteristics of glucose metabolic reprogramming in insulin-sensitive target organs under T2DM conditions, including the liver, skeletal muscle, adipose tissue and pancreatic β-cells. It also discusses four major downstream effector mechanisms: mitochondrial energy metabolism disturbance, augmented oxidative stress, disruption of mitochondria-associated endoplasmic reticulum membranes (MAMs) coupled with calcium homeostasis imbalance, and systemic inflammatory response. On this basis, we summarize the intervention strategies targeting the above signaling pathways, including antioxidant therapy, restoration of MAMs integrity and calcium homeostasis, systemic anti-inflammatory intervention, and multi-target regulatory effects of traditional Chinese medicine. Current studies indicate that early intervention in downstream stress events is induced by glucose metabolic reprogramming. This is particularly true for the preservation of MAMs’ integrity; restoration of calcium homeostasis; and inhibition of NLRP3 inflammasome activation, the latter of which is expected to block or delay the progression from prediabetes to clinical T2DM. Nevertheless, substantial gaps still remain in the understanding of the dynamic regulatory mechanisms of MAMs, tissue-specific therapeutic targets, and relevant clinical translational research. Future integration of multi-omics technologies will provide novel therapeutic strategies and theoretical foundations for the early prevention and treatment of T2DM.
- Open Access
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17
Association between glycated hemoglobin variability and risk of diabetic kidney disease and diabetic retinopathy in diabetic patients: a systematic review and meta-analysis
Objective: To provide a scientific basis for the early prevention of diabetic kidney disease and diabetic retinopathy progression in diabetic patients by systematically evaluating the relationship between glycated hemoglobin (HbA1c) variability and diabetic kidney disease and diabetic retinopathy in these patients. Methods: Databases including PubMed, Web of Science, Cochrane Library, and Embase were searched for studies investigating the association between HbA1c variability and adverse renal events or retinal diseases in diabetic patients, with data collected from the establishment of each database up to August 5, 2025. Two researchers independently conducted literature screening, data extraction, and assessment of the risk of bias in the included studies. Meta-analysis was performed using the Review Manager 5.3 software, with odds ratio (OR) or hazard ratio (HR) as the effect size indicators. Results: A total of 45 cohort studies were included in this study, covering 172,111 participants from 20 countries and regions, of which 22 focused on diabetic kidney events and eight on diabetic retinopathy events, and 15 included both outcomes. For the meta-analysis of the association between HbA1c variability and adverse renal events, the standard deviation (SD) of HbA1c was associated with the risk of adverse renal events in patients with type 1 diabetes mellitus (T1DM), with an HR of 0.97 [95% confidence interval (CI): 0.64–1.48, p = 0.90] and an OR of 1.76 (95% CI: 1.12–2.77, p = 0.01); additionally, for each 1% increase in HbA1c-SD, the incidence of adverse renal events in T1DM patients increased, with an HR of 1.40 (95% CI: 1.23–1.59, p< 0.00001). In patients with type 2 diabetes mellitus (T2DM), the coefficient of variation (CV), SD, and high HbA1c variability score (HVS) of HbA1c were all associated with the mortality of adverse renal events, and all HbA1c variability indicators [CV, CV-per 1% increase, SD, SD-per 1% increase, hemoglobin glycation index (HGI), and HVS] were associated with an increased risk of adverse renal events in this population. For the meta-analysis of the association between HbA1c variability and retinopathy, HbA1c-CV was associated with the risk of retinopathy in T1DM patients, with an HR of 1.15 (95% CI: 1.08–1.22, p< 0.0001); HbA1c-SD was also significantly associated with the risk of retinopathy in T1DM, with an HR of 1.83 (95% CI: 1.28–1.63, p = 0.001) and an OR of 4.89 (95% CI: 1.64–14.65, p = 0.005); in T2DM patients, both HbA1c-CV and SD were significantly associated with the risk of retinopathy, with HRs of 1.12 (95% CI: 1.07–1.17, p< 0.00001) and 1.19 (95% CI: 1.06–1.34, p = 0.003), respectively. Conclusion: HbA1c variability is positively associated with the risks of adverse renal events and retinal diseases in diabetic patients. Therefore, HbA1c variability may play an important and promising role in guiding blood glucose control targets for diabetic patients and predicting the progression of adverse renal events or retinal diseases. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420251133099.
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17
Open AccessAssociation between glycated hemoglobin variability and risk of diabetic kidney disease and diabetic retinopathy in diabetic patients: a systematic review and meta-analysis
Objective: To provide a scientific basis for the early prevention of diabetic kidney disease and diabetic retinopathy progression in diabetic patients by systematically evaluating the relationship between glycated hemoglobin (HbA1c) variability and diabetic kidney disease and diabetic retinopathy in these patients. Methods: Databases including PubMed, Web of Science, Cochrane Library, and Embase were searched for studies investigating the association between HbA1c variability and adverse renal events or retinal diseases in diabetic patients, with data collected from the establishment of each database up to August 5, 2025. Two researchers independently conducted literature screening, data extraction, and assessment of the risk of bias in the included studies. Meta-analysis was performed using the Review Manager 5.3 software, with odds ratio (OR) or hazard ratio (HR) as the effect size indicators. Results: A total of 45 cohort studies were included in this study, covering 172,111 participants from 20 countries and regions, of which 22 focused on diabetic kidney events and eight on diabetic retinopathy events, and 15 included both outcomes. For the meta-analysis of the association between HbA1c variability and adverse renal events, the standard deviation (SD) of HbA1c was associated with the risk of adverse renal events in patients with type 1 diabetes mellitus (T1DM), with an HR of 0.97 [95% confidence interval (CI): 0.64–1.48, p = 0.90] and an OR of 1.76 (95% CI: 1.12–2.77, p = 0.01); additionally, for each 1% increase in HbA1c-SD, the incidence of adverse renal events in T1DM patients increased, with an HR of 1.40 (95% CI: 1.23–1.59, p< 0.00001). In patients with type 2 diabetes mellitus (T2DM), the coefficient of variation (CV), SD, and high HbA1c variability score (HVS) of HbA1c were all associated with the mortality of adverse renal events, and all HbA1c variability indicators [CV, CV-per 1% increase, SD, SD-per 1% increase, hemoglobin glycation index (HGI), and HVS] were associated with an increased risk of adverse renal events in this population. For the meta-analysis of the association between HbA1c variability and retinopathy, HbA1c-CV was associated with the risk of retinopathy in T1DM patients, with an HR of 1.15 (95% CI: 1.08–1.22, p< 0.0001); HbA1c-SD was also significantly associated with the risk of retinopathy in T1DM, with an HR of 1.83 (95% CI: 1.28–1.63, p = 0.001) and an OR of 4.89 (95% CI: 1.64–14.65, p = 0.005); in T2DM patients, both HbA1c-CV and SD were significantly associated with the risk of retinopathy, with HRs of 1.12 (95% CI: 1.07–1.17, p< 0.00001) and 1.19 (95% CI: 1.06–1.34, p = 0.003), respectively. Conclusion: HbA1c variability is positively associated with the risks of adverse renal events and retinal diseases in diabetic patients. Therefore, HbA1c variability may play an important and promising role in guiding blood glucose control targets for diabetic patients and predicting the progression of adverse renal events or retinal diseases. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420251133099.
- Open Access
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1698360
Glycemic variability of glycated hemoglobin in patients with type 2 diabetes mellitus and the risk of cardiovascular diseases: a latest systematic review and meta-analysis
Objective: Glycated hemoglobin (HbA1c) variability is a crucial indicator for evaluating the stability of long-term glycemic control in patients with diabetes mellitus. This study aimed to clarify the association between HbA1c variability and the risk of incident cardiovascular disease (CVD) and mortality in patients with type 2 diabetes mellitus (T2DM) through a systematic review, thereby providing evidence-based support for the early prevention of adverse cardiovascular events in T2DM patients. Methods: We systematically searched the PubMed, Web of Science, The Cochrane Library, and Embase databases for studies on the association between HbA1c variability and cardiovascular outcomes in patients with T2DM, published from the establishment of each database up to August 5, 2025. Cardiovascular outcomes included the incidence of CVD and CVD-related mortality. Two researchers independently conducted literature screening, data extraction, and risk of bias assessment. Meta-analysis was performed using Review Manager 5.3 software, with hazard ratio (HR) or odds ratio (OR) as the effect size. Results: A total of 31 cohort studies were included, covering 545,956 participants from 13 countries and regions. The results of the meta-analysis showed that a higher coefficient of variation (CV) of HbA1c was significantly associated with an increased risk of cardiovascular events (HR = 1.32, 95% CI: 1.18–1.49, P < 0.00001; OR = 1.39, 95% CI: 1.22–1.57, P < 0.00001), and also significantly elevated the risk of mortality (HR = 1.35, 95% CI: 1.16–1.57, P < 0.00001). The standard deviation (SD) of HbA1c was also significantly correlated with a higher risk of cardiovascular events (HR = 1.27, 95% CI: 1.17–1.38, P < 0.00001; OR = 1.30, 95% CI: 1.07–1.57, P = 0.008) and a significant increase in mortality risk (HR = 1.27, 95% CI: 1.17–1.37, P<0.00001). The hemoglobin glycation index (HGI) was significantly associated with the risk of cardiovascular events in terms of HR (HR = 1.36, 95% CI: 1.14–1.62, P = 0.0006), but no statistical significance was observed in terms of OR (OR = 1.47, 95% CI: 0.98–2.20, P = 0.06). In contrast, the HbA1c variability score (HVS) showed no significant association with either the risk of cardiovascular events (HR = 1.31, 95% CI: 0.97–1.78, P = 0.08) or mortality risk (HR = 1.00, 95% CI: 0.76–1.31, P = 1.00). Conclusions: HbA1c variability is positively associated with the risk of adverse cardiovascular events in patients with T2DM. Among the indicators of HbA1c variability, the coefficient of variation (CV), standard deviation (SD), and hemoglobin glycation index (HGI) can serve as significant predictors for the risk of cardiovascular disease (CVD) occurrence and mortality. However, the HbA1c variability score (HVS) did not show significant predictive value in this study. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420251132972.
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1698360
Open AccessGlycemic variability of glycated hemoglobin in patients with type 2 diabetes mellitus and the risk of cardiovascular diseases: a latest systematic review and meta-analysis
Objective: Glycated hemoglobin (HbA1c) variability is a crucial indicator for evaluating the stability of long-term glycemic control in patients with diabetes mellitus. This study aimed to clarify the association between HbA1c variability and the risk of incident cardiovascular disease (CVD) and mortality in patients with type 2 diabetes mellitus (T2DM) through a systematic review, thereby providing evidence-based support for the early prevention of adverse cardiovascular events in T2DM patients. Methods: We systematically searched the PubMed, Web of Science, The Cochrane Library, and Embase databases for studies on the association between HbA1c variability and cardiovascular outcomes in patients with T2DM, published from the establishment of each database up to August 5, 2025. Cardiovascular outcomes included the incidence of CVD and CVD-related mortality. Two researchers independently conducted literature screening, data extraction, and risk of bias assessment. Meta-analysis was performed using Review Manager 5.3 software, with hazard ratio (HR) or odds ratio (OR) as the effect size. Results: A total of 31 cohort studies were included, covering 545,956 participants from 13 countries and regions. The results of the meta-analysis showed that a higher coefficient of variation (CV) of HbA1c was significantly associated with an increased risk of cardiovascular events (HR = 1.32, 95% CI: 1.18–1.49, P < 0.00001; OR = 1.39, 95% CI: 1.22–1.57, P < 0.00001), and also significantly elevated the risk of mortality (HR = 1.35, 95% CI: 1.16–1.57, P < 0.00001). The standard deviation (SD) of HbA1c was also significantly correlated with a higher risk of cardiovascular events (HR = 1.27, 95% CI: 1.17–1.38, P < 0.00001; OR = 1.30, 95% CI: 1.07–1.57, P = 0.008) and a significant increase in mortality risk (HR = 1.27, 95% CI: 1.17–1.37, P<0.00001). The hemoglobin glycation index (HGI) was significantly associated with the risk of cardiovascular events in terms of HR (HR = 1.36, 95% CI: 1.14–1.62, P = 0.0006), but no statistical significance was observed in terms of OR (OR = 1.47, 95% CI: 0.98–2.20, P = 0.06). In contrast, the HbA1c variability score (HVS) showed no significant association with either the risk of cardiovascular events (HR = 1.31, 95% CI: 0.97–1.78, P = 0.08) or mortality risk (HR = 1.00, 95% CI: 0.76–1.31, P = 1.00). Conclusions: HbA1c variability is positively associated with the risk of adverse cardiovascular events in patients with T2DM. Among the indicators of HbA1c variability, the coefficient of variation (CV), standard deviation (SD), and hemoglobin glycation index (HGI) can serve as significant predictors for the risk of cardiovascular disease (CVD) occurrence and mortality. However, the HbA1c variability score (HVS) did not show significant predictive value in this study. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420251132972.
- Open Access
- 18 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1543275
Comparative effectiveness of traditional Chinese medicine injections combined with ACEI/ARB for diabetic nephropathy: A systematic review and network meta-analysis
Aim of the study: This systematic review and network meta-analysis aimed to evaluate the comparative effectiveness of traditional Chinese medicine injections (TCMIs) combined with angiotensin-converting enzyme inhibitors or angiotensin Ⅱ receptor blockers for diabetic nephropathy (DN).Methods: Ten databases were searched. Primary endpoint indicators were urinary albumin excretion rate (UAER) and serum creatinine (Scr). Secondary endpoint indicators were blood urea nitrogen (BUN), urinary β2-microglobulin, total cholesterol, triglyceride, systolic blood pressure, and total effective rate. Cochrane risk of bias tool (version 2.0) was used to evaluate the quality of the studies. The GRADE method was used to assess the whole network. Finally, Stata 16.0 software was used to perform network meta-analysis.Results: A total of 99 randomised controlled trials and ten TCMIs were included for analysis. Based on the surface under the cumulative ranking curve values, it was observed that the efficacy of the combination group was better than that of the control group. For the primary endpoints, the Shuxuetong and Shenkang injections were excellent in reducing UAER and Scr, respectively. The Danshen injection was the most effective for the total effective rate and BUN; the Shuxuetong, Yinxingdamo, Danshen-Chuanxiongqin, and Shuxuening injections were the most effective for total cholesterol, β2-microglobulin, triglyceride, and systolic blood pressure, respectively. In terms of dual indicators, for UAER and Scr, the Danshen injection may be the most effective treatment. In addition, no significant adverse reactions were reported in the relevant studies on the Huangqi and Gegensu injections, whereas the Yinxingdamo, Danshen-Chuanxiongqin, Shenkang, Shuxuetong, and Kudiezi injections demonstrated varying degrees of adverse reactions.Conclusion: In this study, it is indicated that when combined with ACEI/ARB, the Shuxuetong, Shenkang, Danshen, Danshen-Chuanxiongqin, Yinxingdamo, and Shuxuening injections may confer advantages in improving DN indicators. However, due to limitations in the methodological quality of the included studies (especially deficiencies in randomisation and blinding) and the critical lack of reporting on key information regarding TCMI components, the reliability of these findings is compromised.
- 18 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1543275
Open AccessComparative effectiveness of traditional Chinese medicine injections combined with ACEI/ARB for diabetic nephropathy: A systematic review and network meta-analysis
Aim of the study: This systematic review and network meta-analysis aimed to evaluate the comparative effectiveness of traditional Chinese medicine injections (TCMIs) combined with angiotensin-converting enzyme inhibitors or angiotensin Ⅱ receptor blockers for diabetic nephropathy (DN).Methods: Ten databases were searched. Primary endpoint indicators were urinary albumin excretion rate (UAER) and serum creatinine (Scr). Secondary endpoint indicators were blood urea nitrogen (BUN), urinary β2-microglobulin, total cholesterol, triglyceride, systolic blood pressure, and total effective rate. Cochrane risk of bias tool (version 2.0) was used to evaluate the quality of the studies. The GRADE method was used to assess the whole network. Finally, Stata 16.0 software was used to perform network meta-analysis.Results: A total of 99 randomised controlled trials and ten TCMIs were included for analysis. Based on the surface under the cumulative ranking curve values, it was observed that the efficacy of the combination group was better than that of the control group. For the primary endpoints, the Shuxuetong and Shenkang injections were excellent in reducing UAER and Scr, respectively. The Danshen injection was the most effective for the total effective rate and BUN; the Shuxuetong, Yinxingdamo, Danshen-Chuanxiongqin, and Shuxuening injections were the most effective for total cholesterol, β2-microglobulin, triglyceride, and systolic blood pressure, respectively. In terms of dual indicators, for UAER and Scr, the Danshen injection may be the most effective treatment. In addition, no significant adverse reactions were reported in the relevant studies on the Huangqi and Gegensu injections, whereas the Yinxingdamo, Danshen-Chuanxiongqin, Shenkang, Shuxuetong, and Kudiezi injections demonstrated varying degrees of adverse reactions.Conclusion: In this study, it is indicated that when combined with ACEI/ARB, the Shuxuetong, Shenkang, Danshen, Danshen-Chuanxiongqin, Yinxingdamo, and Shuxuening injections may confer advantages in improving DN indicators. However, due to limitations in the methodological quality of the included studies (especially deficiencies in randomisation and blinding) and the critical lack of reporting on key information regarding TCMI components, the reliability of these findings is compromised.
- Open Access
- 15 May 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16  (5) , 100980
Effectiveness and safety of Tongxinluo capsule for diabetic kidney disease: A systematic review and meta-analysis
BACKGROUND Diabetic kidney disease (DKD), a common microvascular complication of diabetes mellitus, is the primary cause of end-stage renal disease. Tongxinluo capsule (TXLC), a traditional Chinese medicinal compound, is widely utilized in China for treating DKD. AIM To analyze the effectiveness and safety of TXLC for treating DKD. METHODS Eight electronic literature databases were retrieved to obtain randomized controlled trials (RCTs) of TXLC for DKD. RevMan 5.3 software was used for data analysis. Evidence quality was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation System. Publication bias was detected using Stata 16.0 software. RESULTS Twenty-two RCTs involving 1941 patients with DKD were identified. Compared with conventional treatment, TXLC combination therapy significantly improved the primary outcomes, including 24-hour urine proteinuria, urine microalbumin, and urinary albumin excretion rate. Regarding secondary outcomes, TXLC combination therapy significantly reduced serum creatinine, blood urea nitrogen, β2-microglobulin, and cystatin C levels; however, it had no significant effect on creatinine clearance rate. In terms of additional outcomes, TXLC combination therapy significantly reduced total cholesterol, triglycerides, low-density lipoprotein cholesterol, fibrinogen, plasma viscosity, whole blood low shear viscosity, whole blood high shear viscosity, and endothelin-1 levels, while increasing nitric oxide levels. However, the addition of TXLC treatment did not significantly affect fasting plasma glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, high-density lipoprotein cholesterol, or C-reactive protein levels. The safety of TXLC in DKD remains uncertain due to limited adverse event reporting. CONCLUSION TXLC may benefit individuals with DKD by improving various health parameters, such as urinary protein levels, renal function, blood lipids, hemorheology, and vascular endothelial function. However, TXLC did not improve all studied outcomes.
- 15 May 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16  (5) , 100980
Open AccessEffectiveness and safety of Tongxinluo capsule for diabetic kidney disease: A systematic review and meta-analysis
BACKGROUND Diabetic kidney disease (DKD), a common microvascular complication of diabetes mellitus, is the primary cause of end-stage renal disease. Tongxinluo capsule (TXLC), a traditional Chinese medicinal compound, is widely utilized in China for treating DKD. AIM To analyze the effectiveness and safety of TXLC for treating DKD. METHODS Eight electronic literature databases were retrieved to obtain randomized controlled trials (RCTs) of TXLC for DKD. RevMan 5.3 software was used for data analysis. Evidence quality was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation System. Publication bias was detected using Stata 16.0 software. RESULTS Twenty-two RCTs involving 1941 patients with DKD were identified. Compared with conventional treatment, TXLC combination therapy significantly improved the primary outcomes, including 24-hour urine proteinuria, urine microalbumin, and urinary albumin excretion rate. Regarding secondary outcomes, TXLC combination therapy significantly reduced serum creatinine, blood urea nitrogen, β2-microglobulin, and cystatin C levels; however, it had no significant effect on creatinine clearance rate. In terms of additional outcomes, TXLC combination therapy significantly reduced total cholesterol, triglycerides, low-density lipoprotein cholesterol, fibrinogen, plasma viscosity, whole blood low shear viscosity, whole blood high shear viscosity, and endothelin-1 levels, while increasing nitric oxide levels. However, the addition of TXLC treatment did not significantly affect fasting plasma glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, high-density lipoprotein cholesterol, or C-reactive protein levels. The safety of TXLC in DKD remains uncertain due to limited adverse event reporting. CONCLUSION TXLC may benefit individuals with DKD by improving various health parameters, such as urinary protein levels, renal function, blood lipids, hemorheology, and vascular endothelial function. However, TXLC did not improve all studied outcomes.
- Open Access
- 24 April 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1557923
Global burden of Type 2 Diabetes Mellitus attributable to dietary risks in elderly adults: insights from the Global Burden of Disease study 2021
Background: Type 2 Diabetes Mellitus (T2DM) poses a significant global health challenge, particularly among elderly adults. Dietary risk factors, such as high consumption of processed meats and sugar-sweetened beverages and low intake of whole grains and fruits, play a critical role in the burden of T2DM. This study aims to comprehensively quantify the global burden of T2DM attributable to dietary risks among elderly adults, identify significant dietary risk factors driving disease burden, and evaluate temporal, regional, and demographic variations to inform targeted public health strategies and interventions for reducing the impact of T2DM.Methods: This study utilized data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 to assess T2DM burden attributable to dietary risks among adults aged 65 years and older across 204 countries and territories. Metrics included age-standardized mortality rates (ASMR) and disability-adjusted life-year rates (ASDR). Dietary risk factors analyzed included low intake of whole grains, fruits, vegetables, and fiber, as well as high intake of processed meat, red meat, and sugar-sweetened beverages. Joinpoint regression and decomposition analyses were performed to examine temporal trends and drivers of changes by region, SDI level, sex, and age.Results: In 2021, dietary risks accounted for 23.61% of T2DM-related deaths and 24.85% of DALYs among elderly adults. ASMR showed a slight decline globally (AAPC: −0.08), while ASDR exhibited a significant upward trend (AAPC: +0.7) from 1990 to 2021. High SDI regions demonstrated decreasing ASMR but persistent DALYs due to prolonged survival with complications. Conversely, low and middle SDI regions exhibited rapid increases in ASMR and ASDR, driven by dietary transitions and limited healthcare resources. Males consistently bore a higher burden than females, with pronounced disparities in low and middle SDI regions. Aging and population growth were the primary drivers of the increasing burden globally.Conclusion: This study underscores the substantial burden of T2DM attributable to dietary risks among elderly adults and highlights significant regional and demographic disparities. Targeted public health interventions, personalized nutritional strategies, and improved healthcare access are essential to mitigate this burden. Future research should explore the impact of emerging dietary trends and precision nutrition on T2DM prevention and management.
- 24 April 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1557923
Open AccessGlobal burden of Type 2 Diabetes Mellitus attributable to dietary risks in elderly adults: insights from the Global Burden of Disease study 2021
Background: Type 2 Diabetes Mellitus (T2DM) poses a significant global health challenge, particularly among elderly adults. Dietary risk factors, such as high consumption of processed meats and sugar-sweetened beverages and low intake of whole grains and fruits, play a critical role in the burden of T2DM. This study aims to comprehensively quantify the global burden of T2DM attributable to dietary risks among elderly adults, identify significant dietary risk factors driving disease burden, and evaluate temporal, regional, and demographic variations to inform targeted public health strategies and interventions for reducing the impact of T2DM.Methods: This study utilized data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 to assess T2DM burden attributable to dietary risks among adults aged 65 years and older across 204 countries and territories. Metrics included age-standardized mortality rates (ASMR) and disability-adjusted life-year rates (ASDR). Dietary risk factors analyzed included low intake of whole grains, fruits, vegetables, and fiber, as well as high intake of processed meat, red meat, and sugar-sweetened beverages. Joinpoint regression and decomposition analyses were performed to examine temporal trends and drivers of changes by region, SDI level, sex, and age.Results: In 2021, dietary risks accounted for 23.61% of T2DM-related deaths and 24.85% of DALYs among elderly adults. ASMR showed a slight decline globally (AAPC: −0.08), while ASDR exhibited a significant upward trend (AAPC: +0.7) from 1990 to 2021. High SDI regions demonstrated decreasing ASMR but persistent DALYs due to prolonged survival with complications. Conversely, low and middle SDI regions exhibited rapid increases in ASMR and ASDR, driven by dietary transitions and limited healthcare resources. Males consistently bore a higher burden than females, with pronounced disparities in low and middle SDI regions. Aging and population growth were the primary drivers of the increasing burden globally.Conclusion: This study underscores the substantial burden of T2DM attributable to dietary risks among elderly adults and highlights significant regional and demographic disparities. Targeted public health interventions, personalized nutritional strategies, and improved healthcare access are essential to mitigate this burden. Future research should explore the impact of emerging dietary trends and precision nutrition on T2DM prevention and management.
- Open Access
- 27 March 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1517272
Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials
Objective: To investigate the safety and clinical efficacy of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and Finerenone in treating patients with type 2 diabetes mellitus (T2DM) combined with non-dialysis chronic kidney disease (CKD).Methods: Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, CQVIP database, and WanFang from their inception up to November 2023 were searched to compare the efficacy and safety of SGLT-2 inhibitors, GLP-1 RA receptor agonists and Finerenone in the treatment of T2DM patients with non-dialysis CKD. To assess the methodological quality and risk of bias in the included studies, we utilized the Cochrane Risk of Bias Assessment tool (RoB 2.0). The confidence of evidence was examined using Confidence in Network Meta-Analysis (CINeMA). Traditional meta-analysis of variables was conducted using Stata 17.0 software with a random-effects model. We assessed publication bias using funnel plots and explored potential sources of heterogeneity through subgroup analysis.Results: A total of 39 studies (99,599 patients) were included. Compared to Placebo (PBO), SGLT-2 inhibitors demonstrated superior efficacy in reducing glycosylated hemoglobin (HbA1c) (MD = −0.33; 95%CI: from −0.52 to −0.15), systolic blood pressure (SBP) (MD from −5.52 to −1.50; 95%CI from −8.80 to −0.23), body weight (MD from −3.81 to −1.29; 95%CI from −6.34 to −0.84) and diastolic blood pressure (DBP) (MD = −1.86; 95%CI: −3.18, −40.54). The efficacy of Liraglutide in reducing Low-Density Lipoprotein Cholesterol (LDL-C) surpassed that of other agents (MD from −1.58 to −1.41; 95%CI from −2.05 to −0.81). Finerenone significantly reduced SBP (MD = −1.65; 95%CI: −2.48, −0.81) compared to PBO. According to the SUCRA based relative ranking of treatments, Empagliflozin was the most effective in reducing HbA1c and DBP. Semaglutide was the least harmful to estimated glomerular filtration rate. Liraglutide was the most effective in reducing LDL-C. Bexagliflozin, Canagliflozin were the most effective in reducing SBP and body weight. Finerenone had the lowest incidence of urinary tract infection, Hypoglycemia was the lowest in the Luseogliflozin group. Ertugliflozin was the least likely to cause acute kidney injury. Canagliflozin had the lowest probability of any adverse event.Conclusion: The safety of these drugs has been confirmed, except for some special drugs. SGLT-2 inhibitors had a preferential glucose-lowering and weight-loss function, GLP-1 receptor agonists had a preferential lowering of LDL-C and blood glucose, and Finereone significantly reduced SBP compared with PBO. Systematic Review Registration: PROSPERO, CRD42024571544.
- 27 March 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1517272
Open AccessClinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials
Objective: To investigate the safety and clinical efficacy of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and Finerenone in treating patients with type 2 diabetes mellitus (T2DM) combined with non-dialysis chronic kidney disease (CKD).Methods: Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, CQVIP database, and WanFang from their inception up to November 2023 were searched to compare the efficacy and safety of SGLT-2 inhibitors, GLP-1 RA receptor agonists and Finerenone in the treatment of T2DM patients with non-dialysis CKD. To assess the methodological quality and risk of bias in the included studies, we utilized the Cochrane Risk of Bias Assessment tool (RoB 2.0). The confidence of evidence was examined using Confidence in Network Meta-Analysis (CINeMA). Traditional meta-analysis of variables was conducted using Stata 17.0 software with a random-effects model. We assessed publication bias using funnel plots and explored potential sources of heterogeneity through subgroup analysis.Results: A total of 39 studies (99,599 patients) were included. Compared to Placebo (PBO), SGLT-2 inhibitors demonstrated superior efficacy in reducing glycosylated hemoglobin (HbA1c) (MD = −0.33; 95%CI: from −0.52 to −0.15), systolic blood pressure (SBP) (MD from −5.52 to −1.50; 95%CI from −8.80 to −0.23), body weight (MD from −3.81 to −1.29; 95%CI from −6.34 to −0.84) and diastolic blood pressure (DBP) (MD = −1.86; 95%CI: −3.18, −40.54). The efficacy of Liraglutide in reducing Low-Density Lipoprotein Cholesterol (LDL-C) surpassed that of other agents (MD from −1.58 to −1.41; 95%CI from −2.05 to −0.81). Finerenone significantly reduced SBP (MD = −1.65; 95%CI: −2.48, −0.81) compared to PBO. According to the SUCRA based relative ranking of treatments, Empagliflozin was the most effective in reducing HbA1c and DBP. Semaglutide was the least harmful to estimated glomerular filtration rate. Liraglutide was the most effective in reducing LDL-C. Bexagliflozin, Canagliflozin were the most effective in reducing SBP and body weight. Finerenone had the lowest incidence of urinary tract infection, Hypoglycemia was the lowest in the Luseogliflozin group. Ertugliflozin was the least likely to cause acute kidney injury. Canagliflozin had the lowest probability of any adverse event.Conclusion: The safety of these drugs has been confirmed, except for some special drugs. SGLT-2 inhibitors had a preferential glucose-lowering and weight-loss function, GLP-1 receptor agonists had a preferential lowering of LDL-C and blood glucose, and Finereone significantly reduced SBP compared with PBO. Systematic Review Registration: PROSPERO, CRD42024571544.
- 26 December 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 341, 119253
Efficacy and safety of Danggui Liuhuang Decoction combined with antithyroid drugs for hyperthyroidism: A systematic review and meta-analysis
- 26 December 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 341, 119253
Efficacy and safety of Danggui Liuhuang Decoction combined with antithyroid drugs for hyperthyroidism: A systematic review and meta-analysis
- Open Access
- 5 March 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16  (1) , 1-9
Associations between type 1 diabetes and pulmonary tuberculosis: a bidirectional mendelian randomization study
Background: Type 1 diabetes mellitus (T1DM) has been associated with higher pulmonary tuberculosis (PTB) risk in observational studies. However, the causal relationship between them remains unclear. This study aimed to assess the causal effect between T1DM and PTB using bidirectional Mendelian randomization (MR) analysis. Methods: Single nucleotide polymorphisms (SNPs) of T1DM and PTB were extracted from the public genetic variation summary database. In addition, GWAS data were collected to explore the causal relationship between PTB and relevant clinical traits of T1DM, including glycemic traits, lipids, and obesity. The inverse variance weighting method (IVW), weighted median method, and MR‒Egger regression were used to evaluate the causal relationship. To ensure the stability of the results, sensitivity analyses assess the robustness of the results by estimating heterogeneity and pleiotropy. Results: IVW showed that T1DM increased the risk of PTB (OR = 1.07, 95% CI: 1.03–1.12, P < 0.001), which was similar to the results of MR‒Egger and weighted median analyses. Moreover, we found that high-density lipoprotein cholesterol (HDL-C; OR = 1.28, 95% CI: 1.03–1.59, P = 0.026) was associated with PTB. There was no evidence of an effect of glycemic traits, remaining lipid markers, or obesity on the risk of PTB. In the reverse MR analysis, no causal relationships were detected for PTB on T1DM and its relevant clinical traits. Conclusion: This study supported that T1DM and HDL-C were risk factors for PTB. This implies the effective role of treating T1DM and managing HDL-C in reducing the risk of PTB, which provides an essential basis for the prevention and comanagement of concurrent T1DM and PTB in clinical practice.
- 5 March 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16  (1) , 1-9
Open AccessAssociations between type 1 diabetes and pulmonary tuberculosis: a bidirectional mendelian randomization study
Background: Type 1 diabetes mellitus (T1DM) has been associated with higher pulmonary tuberculosis (PTB) risk in observational studies. However, the causal relationship between them remains unclear. This study aimed to assess the causal effect between T1DM and PTB using bidirectional Mendelian randomization (MR) analysis. Methods: Single nucleotide polymorphisms (SNPs) of T1DM and PTB were extracted from the public genetic variation summary database. In addition, GWAS data were collected to explore the causal relationship between PTB and relevant clinical traits of T1DM, including glycemic traits, lipids, and obesity. The inverse variance weighting method (IVW), weighted median method, and MR‒Egger regression were used to evaluate the causal relationship. To ensure the stability of the results, sensitivity analyses assess the robustness of the results by estimating heterogeneity and pleiotropy. Results: IVW showed that T1DM increased the risk of PTB (OR = 1.07, 95% CI: 1.03–1.12, P < 0.001), which was similar to the results of MR‒Egger and weighted median analyses. Moreover, we found that high-density lipoprotein cholesterol (HDL-C; OR = 1.28, 95% CI: 1.03–1.59, P = 0.026) was associated with PTB. There was no evidence of an effect of glycemic traits, remaining lipid markers, or obesity on the risk of PTB. In the reverse MR analysis, no causal relationships were detected for PTB on T1DM and its relevant clinical traits. Conclusion: This study supported that T1DM and HDL-C were risk factors for PTB. This implies the effective role of treating T1DM and managing HDL-C in reducing the risk of PTB, which provides an essential basis for the prevention and comanagement of concurrent T1DM and PTB in clinical practice.